RS Cecchini

OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413.

TB Julian, J. P. Costantino, F.A. Vicini et al. · Cancer Research · 2011 · 102 citations

Surgical Oncology, Breast Oncology, Treatment Verification +19

Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

F.A. Vicini, RS Cecchini, JR White et al. · Cancer Research · 2019 · 58 citations

Surgical Oncology, Breast Oncology, Cancer Management +18

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L. Fehrenbacher, RS Cecchini, CE Geyer et al. · Cancer Research · 2018 · 50 citations

Breast Oncology, Cancer Management, Adjuvant Chemotherapy +17

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

MF Rimawi, RS Cecchini, Priya Rastogi et al. · Cancer Research · 2017 · 41 citations

Abstract S3-06, Breast Oncology, Estrogen Receptor +20